{"title": "Sinnlose RSV-Meldepflicht: Folgt eine neue Impfpflicht?", "author": "Resch Media", "url": "https://individuelle-impfentscheidung.de/impfungen/rsv.html", "hostname": "individuelle-impfentscheidung.de", "description": "RSV-Meldepflicht ist sinnlos: Nach der \u00c4nderung des IfSG bef\u00fcrchten die \u00c4FI, dass bald eine weitere Impfpflicht folgen k\u00f6nnte. Lesen Sie hier warum!", "sitename": "individuelle-impfentscheidung.de", "date": "2023-07-10", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Abu-Raya, B., Paramo, M. V., Reicherz, F., & Lavoie, P. M. (2023). Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine, 61.\n[https://doi.org/10.1016/j.eclinm.2023.102089](https://doi.org/10.1016/j.eclinm.2023.102089)\nAzzari, C., Baraldi, E., Bonanni, P., Bozzola, E., Coscia, A., Lanari, M., Manzoni, P., Mazzone, T., Sandri, F., Checcucci Lisi, G., Parisi, S., Piacentini, G., & Mosca, F. (2021). Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Italian Journal of Pediatrics, 47(1), 198.\n[https://doi.org/10.1186/s13052-021-01148-8](https://doi.org/10.1186/s13052-021-01148-8)\nBardach, A., Rey-Ares, L., Cafferata, M. L., Cormick, G., Romano, M., Ruvinsky, S., & Savy, V. (2014).\n[Systematic review](/glossar.html#c233) and meta-analysis of respiratory syncytial virus infection epidemiology in Latin America. Reviews in Medical Virology, 24(2), 76\u201389. [https://doi.org/10.1002/rmv.1775](https://doi.org/10.1002/rmv.1775)\nBeem, M., Wright, F. H., Hamre, D., Egerer, R., & Oehme, M. (1960). Association of the Chimpanzee Coryza Agent with Acute Respiratory Disease in Children. New England Journal of Medicine, 263(11), 523\u2013530.\n[https://doi.org/10.1056/NEJM196009152631101](https://doi.org/10.1056/NEJM196009152631101)\nBergeron, H. C., & Tripp, R. A. (2021). Immunopathology of RSV: An Updated Review. Viruses, 13(12), 2478.\n[https://doi.org/10.3390/v13122478](https://doi.org/10.3390/v13122478)\nBoytchev, H. (2023). Maternal RSV vaccine: Further analysis is urged on preterm births. BMJ, 381, p1021.\n[https://doi.org/10.1136/bmj.p1021](https://doi.org/10.1136/bmj.p1021)\nBuchholz, U., Lehfeld, A.-S., Tolksdorf, K., Cai, W., Reiche, J., Biere, B., D\u00fcrrwald, R., & Buda, S. (2023). Respiratory infections in children and adolescents in Germany during the COVID-19 pandemic. Journal of Health Monitoring, 8(2), 20\u201338.\n[https://doi.org/10.25646/11437](https://doi.org/10.25646/11437)\nBundesregierung. (2023, Juni 23). Antwort der Bundesregierung auf die Kleine Anfrage der Fraktion der CDU/CSU (Drucksache 20/7143). Deutscher Bundestag (20. Wahlperiode).\n[https://dserver.bundestag.de/btd/20/074/2007439.pdf](https://dserver.bundestag.de/btd/20/074/2007439.pdf)\nBylsma, L. C., Suh, M., Movva, N., Fryzek, J. P., & Nelson, C. B. (2022). Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature Review. The Journal of Infectious Diseases, 226(Supplement_2), S267\u2013S281.\n[https://doi.org/10.1093/infdis/jiac226](https://doi.org/10.1093/infdis/jiac226)\nCai, W., D\u00fcrrwald, R., Biere, B., Schweiger, B., Haas, W., Wolff, T., Buda, S., & Reiche, J. (2022). Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011\u20132021, Germany. Influenza and Other Respiratory Viruses, 16(5), 854\u2013857.\n[https://doi.org/10.1111/irv.12996](https://doi.org/10.1111/irv.12996)\nCenters for Disease Control and Prevention. (2023). Evidence to Recommendations Framework: Pfizers Maternal RSVpreF Vaccine.\nCollins, P. L., & Graham, B. S. (2008). Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. Journal of Virology, 82(5), 2040\u2013\n[2055. https://doi.org/10.1128/jvi.01625-07](http://2055.)\nCong, B., Dighero, I., Zhang, T., Chung, A., Nair, H., & Li, Y. (2023). Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: A systematic analysis. BMC Medicine, 21(1), 224.\n[https://doi.org/10.1186/s12916-023-02932-5](https://doi.org/10.1186/s12916-023-02932-5)\nDeutsche Gesellschaft f\u00fcr p\u00e4diatrische Infektiologie e.V. (2018). LL AWMF 048-012-Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern.\n[https://register.awmf.org/assets/guidelines/048-012l_S2k_Prophylaxe-von-schweren_RSV-Erkrankungen-Risikokindern-Palivizumab_2018-11.pdf](https://register.awmf.org/assets/guidelines/048-012l_S2k_Prophylaxe-von-schweren_RSV-Erkrankungen-Risikokindern-Palivizumab_2018-11.pdf)\nDeutsche Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie e.V., Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin e.V., Gesellschaft f\u00fcr Virologie e.V., Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Kardiologie und Angeborene Herzfehler e.V., Gesellschaft f\u00fcr Neonatologie und p\u00e4diatrische Intensivmedizin e.V., Gesellschaft f\u00fcr P\u00e4diatrische Pneumologie e.V., Berufsverband der Kinder- und Jugend\u00e4rzte, & Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.V. (2018, August 31). S2k-Leitlinie Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern. AWMF Leitlinien Register.\n[https://register.awmf.org/de/leitlinien/detail/048-012](https://register.awmf.org/de/leitlinien/detail/048-012)\nDi Mattia, G., Nenna, R., Mancino, E., Rizzo, V., Pierangeli, A., Villani, A., & Midulla, F. (2021). During the COVID\u201019 pandemic where has respiratory syncytial virus gone? Pediatric Pulmonology, 56(10), 3106\u20133109.\n[https://doi.org/10.1002/ppul.25582](https://doi.org/10.1002/ppul.25582)\nEurop\u00e4ische Kommission. (2023a, Juni 6). EU genehmigt ersten Impfstoff zum Schutz \u00e4lterer Erwachsener vor Infektion mit dem Atemwegs-Virus RSV. Pressemitteilung.\n[https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-alterer-erwachsener-vor-infektion-mit-dem-atemwegs-virus-2023-06-06_de](https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-alterer-erwachsener-vor-infektion-mit-dem-atemwegs-virus-2023-06-06_de)\nEurop\u00e4ische Kommission. (2023b, August 25). EU genehmigt ersten Impfstoff zum Schutz von S\u00e4uglingen vor RSV-Infektionen. Pressemitteilung.\n[https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-von-sauglingen-vor-rsv-infektionen-2023-08-25_de](https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-von-sauglingen-vor-rsv-infektionen-2023-08-25_de)\nEuropean Medicines Agency. (2009). Fachinformation Palivizumab.\n[https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_de.pdf](https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_de.pdf)\nEuropean Medicines Agency. (2022). Fachinformation Nirsevimab (Beyfortus).\n[https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf](https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf)\nEuropean Medicines Agency. (2023). Fachinformation Arexvy.\n[https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.pdf](https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.pdf)\nFood and Drug Administration. (2023). Fachinformation Abrysvo.\n[https://www.fda.gov/media/168889/download](https://www.fda.gov/media/168889/download)\nGalanti, M., Birger, R., Ud-Dean, M., Filip, I., Morita, H., Comito, D., Anthony, S., Freyer, G. A., Ibrahim, S., Lane, B., Matienzo, N., Ligon, C., Rabadan, R., Shittu, A., Tagne, E., & Shaman, J. (2019). Rates of asymptomatic respiratory virus infection across age groups. Epidemiology and Infection, 147, e176.\n[https://doi.org/10.1017/S0950268819000505](https://doi.org/10.1017/S0950268819000505)\nGaregnani, L., Styrmisd\u00f3ttir, L., Roson Rodriguez, P., Escobar Liquitay, C. M., Esteban, I., & Franco, J. V. (2021). Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. The\n[Cochrane](/glossar.html#c64) Database of Systematic Reviews, 2021(11), CD013757. [https://doi.org/10.1002/14651858.CD013757.pub2](https://doi.org/10.1002/14651858.CD013757.pub2)\nHammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Grenham, A., W\u00e4hlby Hamr\u00e9n, U., Mankad, V. S., Ren, P., Takas, T., Abram, M. E., Leach, A., Griffin, M. P., & Villafana, T. (2022). Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. New England Journal of Medicine, 386(9), 837\u2013846.\n[https://doi.org/10.1056/NEJMoa2110275](https://doi.org/10.1056/NEJMoa2110275)\nHansen, C. L., Chaves, S. S., Demont, C., & Viboud, C. (2022). Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. JAMA Network Open, 5(2), e220527.\n[https://doi.org/10.1001/jamanetworkopen.2022.0527](https://doi.org/10.1001/jamanetworkopen.2022.0527)\nJain, H., Schweitzer, J. W., & Justice, N. A. (2023). Respiratory Syncytial Virus Infection. In StatPearls. StatPearls Publishing.\n[http://www.ncbi.nlm.nih.gov/books/NBK459215/](http://www.ncbi.nlm.nih.gov/books/NBK459215/)\nKaler, J., Hussain, A., Patel, K., Hernandez, T., & Ray, S. (2023). Respiratory Syncytial Virus: A Comprehensive Review of\n[Transmission](/glossar.html#c145), Pathophysiology, and Manifestation. Cureus, 15(3), e36342. [https://doi.org/10.7759/cureus.36342](https://doi.org/10.7759/cureus.36342)\nKampmann, B., Madhi, S. A., Munjal, I., Sim\u00f5es, E. A. F., Pahud, B. A., Llapur, C., Baker, J., P\u00e9rez Marc, G., Radley, D., Shittu, E., Glanternik, J., Snaggs, H., Baber, J., Zachariah, P., Barnabas, S. L., Fausett, M., Adam, T., Perreras, N., Van Houten, M. A., \u2026 Gurtman, A. (2023).\n[Bivalent](/glossar.html#c142) Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. New England Journal of Medicine, 388(16), 1451\u20131464. [https://doi.org/10.1056/NEJMoa2216480](https://doi.org/10.1056/NEJMoa2216480)\nLi, Y., Kulkarni, D., Begier, E., Wahi-Singh, P., Wahi-Singh, B., Gessner, B., & Nair, H. (2023). Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: A Systematic Review and Modelling Study. Infectious Diseases and Therapy, 12(4), 1137\u20131149.\n[https://doi.org/10.1007/s40121-023-00792-3](https://doi.org/10.1007/s40121-023-00792-3)\nLi, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., Madhi, S. A., Omer, S. B., Sim\u00f5es, E. A. F., Campbell, H., Pariente, A. B., Bardach, D., Bassat, Q., Casalegno, J.-S., Chakhunashvili, G., Crawford, N., Danilenko, D., Do, L. A. H., Echavarria, M., \u2026 RESCEU investigators. (2022). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet (London, England), 399(10340), 2047\u20132064.\n[https://doi.org/10.1016/S0140-6736(22)00478-0](https://doi.org/10.1016/S0140-6736(22)00478-0)\nLong, C. E., McBride, J. T., & Hall, C. B. (1995). Sequelae of respiratory syncytial virus infections. A role for intervention studies. American Journal of Respiratory and Critical Care Medicine, 151(5), 1678\u20131680; discussion 1680-1681.\n[https://doi.org/10.1164/ajrccm/151.5_Pt_1.1678](https://doi.org/10.1164/ajrccm/151.5_Pt_1.1678)\nLumley, S. F., Richens, N., Lees, E., Cregan, J., Kalimeris, E., Oakley, S., Morgan, M., Segal, S., Dawson, M., Walker, A. S., Eyre, D. W., Crook, D. W., Beer, S., Novak, A., Stoesser, N. E., & Matthews, P. C. (2022). Changes in paediatric respiratory infections at a UK teaching hospital 2016\u20132021; impact of the SARS-CoV-2 pandemic. Journal of Infection, 84(1), 40\u201347.\n[https://doi.org/10.1016/j.jinf.2021.10.022](https://doi.org/10.1016/j.jinf.2021.10.022)\nMaggi, S., Veronese, N., Burgio, M., Cammarata, G., Ciuppa, M. E., Ciriminna, S., Di Gennaro, F., Smith, L., Trott, M., Dominguez, L. J., Giammanco, G. M., De Grazia, S., Costantino, C., Vitale, F., & Barbagallo, M. (2022). Rate of Hospitalizations and Mortality of Respiratory Syncytial Virus Infection Compared to Influenza in Older People: A Systematic Review and Meta-Analysis. Vaccines, 10(12), 2092.\n[https://doi.org/10.3390/vaccines10122092](https://doi.org/10.3390/vaccines10122092)\nMalloy, A. M. W., Falsey, A. R., & Ruckwardt, T. J. (2013). Consequences of immature and senescent\n[immune](/glossar.html#c47) responses for infection with respiratory syncytial virus. Current Topics in Microbiology and Immunology, 372, 211\u2013231. [https://doi.org/10.1007/978-3-642-38919-1_11](https://doi.org/10.1007/978-3-642-38919-1_11)\nMcNamara, P. S., & Smyth, R. L. (2002). The pathogenesis of respiratory syncytial virus disease in childhood. British Medical Bulletin, 61(1), 13\u201328.\n[https://doi.org/10.1093/bmb/61.1.13](https://doi.org/10.1093/bmb/61.1.13)\nMuller, W. J., Madhi, S. A., Seoane Nu\u00f1ez, B., Baca Cots, M., Bosheva, M., Dagan, R., Hammitt, L. L., Llapur, C. J., Novoa, J. M., Saez Llorens, X., Grenham, A., Kelly, E. J., Mankad, V. S., Shroff, M., Takas, T., Leach, A., & Villafana, T. (2023). Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. New England Journal of Medicine, 388(16), 1533\u20131534.\n[https://doi.org/10.1056/NEJMc2214773](https://doi.org/10.1056/NEJMc2214773)\nMunywoki, P. K., Koech, D. C., Agoti, C. N., Bett, A., Cane, P. A., Medley, G. F., & Nokes, D. J. (2015). Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household Cohort. The Journal of Infectious Diseases, 212(11), 1711\u20131718.\n[https://doi.org/10.1093/infdis/jiv263](https://doi.org/10.1093/infdis/jiv263)\nPATH. (2023, Juni). RSV Vaccine and mAb Snapshot. Path.Org.\n[https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/](https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/)\nRobert Koch-Institut. (2015, Februar 9). Paramyxoviren. EM-Aufnahmen.\n[https://www.rki.de/DE/Content/Infekt/NRZ/EM/Aufnahmen/EM-Tab_Paramyxoviren.html](https://www.rki.de/DE/Content/Infekt/NRZ/EM/Aufnahmen/EM-Tab_Paramyxoviren.html)\nRobert Koch-Institut. (2018, Februar 6).\n[Respiratorische](/glossar.html#c123) Synzytial-Virus-Infektionen (RSV). RKI-Ratgeber. [https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_RSV.html](https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_RSV.html)\nRobert Koch-Institut. (2023, Juli 25). Aktuelle Themensetzung. St\u00e4ndige Impfkommission.\n[https://www.rki.de/DE/Content/Kommissionen/STIKO/AktuelleThemensetzung/AktuelleThemensetzung_node.html](https://www.rki.de/DE/Content/Kommissionen/STIKO/AktuelleThemensetzung/AktuelleThemensetzung_node.html)\nRohde, G., Schultze-Werninghaus, G., & Bauer, T. T. (2004). Therapie viraler Atemwegsinfekte. Der Internist, 45(4), 468\u2013475.\n[https://doi.org/10.1007/s00108-003-1111-5](https://doi.org/10.1007/s00108-003-1111-5)\nRozenbaum, M. H., Begier, E., Kurosky, S. K., Whelan, J., Bem, D., Pouwels, K. B., Postma, M., & Bont, L. (2023). Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infectious Diseases and Therapy, 12(6), 1487\u20131504.\n[https://doi.org/10.1007/s40121-023-00802-4](https://doi.org/10.1007/s40121-023-00802-4)\nShi, T., Balsells, E., Wastnedge, E., Singleton, R., Rasmussen, Z. A., Zar, H. J., Rath, B. A., Madhi, S. A., Campbell, S., Vaccari, L. C., Bulkow, L. R., Thomas, E. D., Barnett, W., Hoppe, C., Campbell, H., & Nair, H. (2015). Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. Journal of Global Health, 5(2), 020416.\n[https://doi.org/10.7189/jogh.05.020416](https://doi.org/10.7189/jogh.05.020416)\nShi, T., Ooi, Y., Zaw, E. M., Utjesanovic, N., Campbell, H., Cunningham, S., Bont, L., Nair, H., & RESCEU Investigators. (2020). Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood. The Journal of Infectious Diseases, 222(Supplement_7), S628\u2013S633.\n[https://doi.org/10.1093/infdis/jiz311](https://doi.org/10.1093/infdis/jiz311)\nShi, T., Vennard, S., Jasiewicz, F., Brogden, R., Nair, H., & RESCEU Investigators. (2022). Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases, 226(Suppl 1), S17\u2013S21.\n[https://doi.org/10.1093/infdis/jiab040](https://doi.org/10.1093/infdis/jiab040)\nSim\u00f5es, E. A. F., Madhi, S. A., Muller, W. J., Atanasova, V., Bosheva, M., Caba\u00f1as, F., Baca Cots, M., Domachowske, J. B., Garcia-Garcia, M. L., Grantina, I., Nguyen, K. A., Zar, H. J., Berglind, A., Cummings, C., Griffin, M. P., Takas, T., Yuan, Y., W\u00e4hlby Hamr\u00e9n, U., Leach, A., & Villafana, T. (2023). Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials. The Lancet. Child & Adolescent Health, 7(3), 180\u2013189.\n[https://doi.org/10.1016/S2352-4642(22)00321-2](https://doi.org/10.1016/S2352-4642(22)00321-2)\nTenenbaum, T., Doenhardt, M., Diffloth, N., Berner, R., & Armann, J. P. (2022). High burden of RSV hospitalizations in Germany 2021-2022. Infection, 50(6), 1587\u20131590.\n[https://doi.org/10.1007/s15010-022-01889-6](https://doi.org/10.1007/s15010-022-01889-6)\nVerwey, C., Nunes, M. C., Dangor, Z., & Madhi, S. A. (2020). Pulmonary function sequelae after respiratory syncytial virus lower respiratory tract infection in children: A systematic review. Pediatric Pulmonology, 55(7), 1567\u20131583.\n[https://doi.org/10.1002/ppul.24804](https://doi.org/10.1002/ppul.24804)\nWeigl, J. a. I., Puppe, W., Belke, O., Neus\u00fc\u00df, J., Bagci, F., & Schmitt, H. J. (2005). The Descriptive Epidemiology of Severe Lower Respiratory Tract Infections in Children in Kiel, Germany. Klinische P\u00e4diatrie, 217(5), 259\u2013267.\n[https://doi.org/10.1055/s-2004-820352](https://doi.org/10.1055/s-2004-820352)", "language": null, "image": null, "pagetype": "article", "links": ["/", "/", "https://easyverein.com/public/AeIIE2019/", "https://forum.individuelle-impfentscheidung.de", "/impfungen/rsv.html", "/", "/aktuelles.html", "/aktuelles/covid-19-impfpflicht.html", "/aktuelles/covid-19-impfung.html", "/aktuelles/covid-19-bei-kindern-und-jugendlichen.html", "/aktuelles/covid-19-impfpflicht-verfassungsbeschwerden.html", "/masern-impfpflicht-verfassungsbeschwerden.html", "/aktuelles/masern-impfpflicht.html", "/standpunkte.html", "/standpunkte/publikationen.html", "/standpunkte/faqs.html", "/standpunkte/podcasts.html", "/standpunkte/videos.html", "/standpunkte/twitter.html", "/newsletter/standard-titel.html", "/aktionen.html", "/aktionen/lauterdnaimstoff.html", "/aktionen/ifsgehtsogarnicht.html", "/standpunkt/profisgegenimpfpflicht.html", "/impfenohnepflicht.html", "/briefaktion.html", "/aktuelles/die-corona-impfpflicht-ist-das-falsche-instrument-1.html", "/aktionen/keine-impfpflicht-fuer-beschaeftigte-im-medizinischen-und-sozialen-bereich.html", "/2ggehtgarnicht-1.html", "/aktuelles/nichtmeinaerztetag.html", "/aktuelles/deutschland-braucht-keine-impfpflicht.html", "/impfungen.html", "/impfungen/covid-19.html", "/impfungen/diphtherie.html", "/impfungen/fsme.html", "/impfungen/guertelrose.html", "/impfungen/hpv.html", "/impfungen/influenza.html", "/impfungen/masern.html", "/impfungen/meningokokken.html", "/impfungen/mumps.html", "/impfungen/polio.html", "/impfungen/roeteln.html", "/impfungen/rsv.html", "/impfungen/tetanus.html", "/impfungen/windpocken.html", "/impfempfehlungen.html", "/wer-wir-sind/arztsuche.html", "/impfempfehlungen/alternative-impfstrategien.html", "/impfempfehlungen/leitbild.html", "/impfempfehlungen/off-label-use.html", "/wer-wir-sind.html", "/wer-wir-sind/vorstand.html", "/wer-wir-sind/mitarbeiterinnen.html", "/wer-wir-sind/leitbild.html", "/wer-wir-sind/satzung.html", "/wer-wir-sind/transparenz.html", "/wer-wir-sind/gruendung.html", "/wer-wir-sind/wie-wir-arbeiten.html", "/wer-wir-sind/mitglied-werden.html", "/presse.html", "/presse/pressebilder.html", "/newsletter.html", "/newsletter/archiv.html", "/mitglied-werden.html", "/spenden.html", "https://twitter.com/individ_impfen", "https://www.linkedin.com/company/individuelle-impfentscheidung", "https://www.instagram.com/individuelle_impfentscheidung/", "https://www.youtube.com/channel/UCCppnAfYzQaf2ruYrvqH5rA/featured", "https://odysee.com/@individuelle_impfentscheidung:3", "https://open.spotify.com/show/7jgmUbf87g4Ha0whVGaIAp?si=53cbfd723be44076", "/", "/impfungen.html", "/impfungen/rsv.html", "/fileadmin/Fachbeitr%C3%A4ge/RSV/AEFI_RSV-One-Pager.pdf", "/wer-wir-sind/wie-wir-arbeiten.html", "/standpunkte/podcasts.html", "/glossar.html#c147", "/glossar.html#c25", "/glossar.html#c276", "/glossar.html#c80", "/glossar.html#c277", "https://individuelle-impfentscheidung.de/fileadmin/Fachbeitr\u00e4ge/RSV/RSV_EM_10_67878_JPG.jpg", "/glossar.html#c4", "/glossar.html#c70", "/glossar.html#c84", "/glossar.html#c124", "/glossar.html#c278", "/glossar.html#c95", "/glossar.html#c62", "/glossar.html#c46", "/glossar.html#c21", "/glossar.html#c37", "/glossar.html#c280", "/glossar.html#c282", "/glossar.html#c43", "/glossar.html#c279", "/glossar.html#c281", "/glossar.html#c225", "/glossar.html#c157", "/glossar.html#c283", "/glossar.html#c131", "https://individuelle-impfentscheidung.de/fileadmin/Fachbeitr\u00e4ge/RSV/RSV_Flussdiagramm_01.pdf", "/glossar.html#c13", "/glossar.html#c284", "/glossar.html#c102", "/glossar.html#c40", "/glossar.html#c285", "/glossar.html#c286", "/glossar.html#c287", "/glossar.html#c288", "/glossar.html#c78", "/glossar.html#c289", "/glossar.html#c90", "/glossar.html#c290", "#c922", "/glossar.html#c260", "/glossar.html#c293", "/glossar.html#c196", "/glossar.html#c309", "/glossar.html#c171", "/glossar.html#c291", "/glossar.html#c8", "/glossar.html#c292", "/glossar.html#c270", "https://individuelle-impfentscheidung.de/fileadmin/Fachbeitr\u00e4ge/RSV/irv12996-fig-0003-m.jpg", "/glossar.html#c94", "/glossar.html#c9", "/glossar.html#c140", "/glossar.html#c20", "/glossar.html#c295", "https://individuelle-impfentscheidung.de/fileadmin/Fachbeitr\u00e4ge/RSV/RSV-snapshot_02JUN2023_clinical-stage_dBtD8W3.pdf", "/glossar.html#c143", "/glossar.html#c299", "/glossar.html#c10", "/glossar.html#c190", "/glossar.html#c169", "/glossar.html#c176", "/glossar.html#c109", "/glossar.html#c193", "/glossar.html#c187", "/glossar.html#c153", "/glossar.html#c101", "/glossar.html#c133", "/glossar.html#c294", "/glossar.html#c50", "https://de.wikipedia.org/wiki/Omnibusverfahren", "https://dserver.bundestag.de/btd/20/072/2007235.pdf", "https://www.welt.de/politik/deutschland/plus246252920/Infektionsschutz-Diese-neue-Meldepflicht-braucht-es-nicht.html", "https://www.epochtimes.de/politik/deutschland/bundesregierung-beschliesst-meldepflicht-fuer-erkaeltungskrankheit-a4326244.html", "https://www.presseportal.de/pm/162064/5553872", "#", "#", "https://doi.org/10.1016/j.eclinm.2023.102089", "https://doi.org/10.1186/s13052-021-01148-8", "/glossar.html#c233", "https://doi.org/10.1002/rmv.1775", "https://doi.org/10.1056/NEJM196009152631101", "https://doi.org/10.3390/v13122478", "https://doi.org/10.1136/bmj.p1021", "https://doi.org/10.25646/11437", "https://dserver.bundestag.de/btd/20/074/2007439.pdf", "https://doi.org/10.1093/infdis/jiac226", "https://doi.org/10.1111/irv.12996", "http://2055.", "https://doi.org/10.1186/s12916-023-02932-5", "https://register.awmf.org/assets/guidelines/048-012l_S2k_Prophylaxe-von-schweren_RSV-Erkrankungen-Risikokindern-Palivizumab_2018-11.pdf", "https://register.awmf.org/de/leitlinien/detail/048-012", "https://doi.org/10.1002/ppul.25582", "https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-alterer-erwachsener-vor-infektion-mit-dem-atemwegs-virus-2023-06-06_de", "https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-von-sauglingen-vor-rsv-infektionen-2023-08-25_de", "https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_de.pdf", "https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.pdf", "https://www.fda.gov/media/168889/download", "https://doi.org/10.1017/S0950268819000505", "/glossar.html#c64", "https://doi.org/10.1002/14651858.CD013757.pub2", "https://doi.org/10.1056/NEJMoa2110275", "https://doi.org/10.1001/jamanetworkopen.2022.0527", "http://www.ncbi.nlm.nih.gov/books/NBK459215/", "/glossar.html#c145", "https://doi.org/10.7759/cureus.36342", "/glossar.html#c142", "https://doi.org/10.1056/NEJMoa2216480", "https://doi.org/10.1007/s40121-023-00792-3", "https://doi.org/10.1016/S0140-6736(22)00478-0", "https://doi.org/10.1164/ajrccm/151.5_Pt_1.1678", "https://doi.org/10.1016/j.jinf.2021.10.022", "https://doi.org/10.3390/vaccines10122092", "/glossar.html#c47", "https://doi.org/10.1007/978-3-642-38919-1_11", "https://doi.org/10.1093/bmb/61.1.13", "https://doi.org/10.1056/NEJMc2214773", "https://doi.org/10.1093/infdis/jiv263", "https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/", "https://www.rki.de/DE/Content/Infekt/NRZ/EM/Aufnahmen/EM-Tab_Paramyxoviren.html", "/glossar.html#c123", "https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_RSV.html", "https://www.rki.de/DE/Content/Kommissionen/STIKO/AktuelleThemensetzung/AktuelleThemensetzung_node.html", "https://doi.org/10.1007/s00108-003-1111-5", "https://doi.org/10.1007/s40121-023-00802-4", "https://doi.org/10.7189/jogh.05.020416", "https://doi.org/10.1093/infdis/jiz311", "https://doi.org/10.1093/infdis/jiab040", "https://doi.org/10.1016/S2352-4642(22)00321-2", "https://doi.org/10.1007/s15010-022-01889-6", "https://doi.org/10.1002/ppul.24804", "https://doi.org/10.1055/s-2004-820352", "/", "/aktuelles.html", "/standpunkte.html", "/aktionen.html", "/impfungen.html", "/impfempfehlungen.html", "/wer-wir-sind.html", "/presse.html", "/newsletter.html", "/mitglied-werden.html", "/spenden.html", "/standpunkte.html", "/standpunkte/publikationen.html", "/standpunkte/faqs.html", "/standpunkte/podcasts.html", "/standpunkte/videos.html", "/standpunkte/twitter.html", "/newsletter/standard-titel.html", "/impfungen.html", "/impfungen/covid-19.html", "/impfungen/diphtherie.html", "/impfungen/fsme.html", "/impfungen/guertelrose.html", "/impfungen/hpv.html", "/impfungen/influenza.html", "/impfungen/masern.html", "/impfungen/meningokokken.html", "/impfungen/mumps.html", "/impfungen/polio.html", "/impfungen/roeteln.html", "/impfungen/rsv.html", "/impfungen/tetanus.html", "/impfungen/windpocken.html", "/wer-wir-sind.html", "/wer-wir-sind/vorstand.html", "/wer-wir-sind/mitarbeiterinnen.html", "/wer-wir-sind/leitbild.html", "/wer-wir-sind/satzung.html", "/wer-wir-sind/transparenz.html", "/wer-wir-sind/gruendung.html", "/wer-wir-sind/wie-wir-arbeiten.html", "/datenschutz.html", "/impressum.html", "", "https://twitter.com/individ_impfen", "https://www.linkedin.com/company/individuelle-impfentscheidung", "https://www.instagram.com/individuelle_impfentscheidung/", "https://www.youtube.com/channel/UCCppnAfYzQaf2ruYrvqH5rA/featured", "https://odysee.com/@individuelle_impfentscheidung:3", "https://open.spotify.com/show/7jgmUbf87g4Ha0whVGaIAp?si=53cbfd723be44076", "/datenschutz.html", null, "/datenschutz.html", null, null, null, "https://forum.individuelle-impfentscheidung.de", "/impfungen/rsv.html", "https://easyverein.com/public/AeIIE2019/applicationform/", "/impfungen/rsv.html", "https://easyverein.com/public/AeIIE2019", "/impfungen/rsv.html", "https://easyverein.com/public/AeIIE2019/applicationform/", "/impfungen/rsv.html"]}